Search

Your search keyword '"Carraro M"' showing total 263 results
Start Over Author "Carraro M" Search Limiters Full Text
263 results on '"Carraro M"'

1. A nanoporous surface is essential for glomerular podocyte differentiation in three-dimensional culture

Author

Zennaro C, Rastaldi MP, Bakeine GJ, Delfino R, Tonon F, Farra R, Grassi G, Artero M, Tormen M, and Carraro M

Subjects
podocytes, neurons, nanotechnology, basement membrane, differentiation, adhesion, Medicine (General), R5-920
Abstract

Cristina Zennaro,1 Maria Pia Rastaldi,2 Gerald James Bakeine,3 Riccarda Delfino,1 Federica Tonon,1 Rossella Farra,4 Gabriele Grassi,1,5 Mary Artero,6 Massimo Tormen,7 Michele Carraro1 1Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 3Department of Radiology, San Martino University Hospital, University of Genoa, Genoa, 4Department of Engineering and Architecture, University of Trieste, 5Department of Life Sciences, Cattinara University Hospital, University of Trieste, 6Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, 7IOM-CNR Area Science Park, Trieste, Italy Abstract: Although it is well recognized that cell–matrix interactions are based on both molecular and geometrical characteristics, the relationship between specific cell types and the three-dimensional morphology of the surface to which they are attached is poorly understood. This is particularly true for glomerular podocytes – the gatekeepers of glomerular filtration – which completely enwrap the glomerular basement membrane with their primary and secondary ramifications. Nanotechnologies produce biocompatible materials which offer the possibility to build substrates which differ only by topology in order to mimic the spatial organization of diverse basement membranes. With this in mind, we produced and utilized rough and porous surfaces obtained from silicon to analyze the behavior of two diverse ramified cells: glomerular podocytes and a neuronal cell line used as a control. Proper differentiation and development of ramifications of both cell types was largely influenced by topographical characteristics. Confirming previous data, the neuronal cell line acquired features of maturation on rough nanosurfaces. In contrast, podocytes developed and matured preferentially on nanoporous surfaces provided with grooves, as shown by the organization of the actin cytoskeleton stress fibers and the proper development of vinculin-positive focal adhesions. On the basis of these findings, we suggest that in vitro studies regarding podocyte attachment to the glomerular basement membrane should take into account the geometrical properties of the surface on which the tests are conducted because physiological cellular activity depends on the three-dimensional microenvironment. Keywords: podocytes, neurons, nanotechnology, basement membrane, differentiation, adhesion

Published
2016

3. Optimizing the ITER NBI ion source by dedicated RF driver test stand

Author

Mario, I., primary, Pimazzoni, A., additional, Sartori, E., additional, Pouradier-Duteil, B., additional, Sheperd, A., additional, Denizeau, S., additional, Casagrande, R., additional, Agnello, R., additional, Agostini, M., additional, Aprile, D., additional, Barbato, P., additional, Baseggio, L., additional, Battistella, M., additional, Berton, G., additional, Boldrin, M., additional, Brombin, M., additional, Candeloro, V., additional, Carraro, M., additional, Cinetto, P., additional, Dal Bello, S., additional, Delogu, R., additional, Fadone, M., additional, Fellin, F., additional, Fincato, M., additional, Franchin, L., additional, Friso, D., additional, Grando, L., additional, La Rosa, A., additional, Laterza, B., additional, López-Bruna, D., additional, Magagna, M., additional, Maniero, M., additional, Marconato, N., additional, Pasqualotto, R., additional, Passalacqua, G., additional, Pavei, M., additional, Poggi, C., additional, Ravarotto, D., additional, Rigoni-Garola, A., additional, Romanato, L., additional, Rossetto, F., additional, Segalini, B., additional, Sonato, P., additional, Taliercio, C., additional, Toigo, V., additional, Tollin, M., additional, Ugoletti, M., additional, Vignando, M., additional, Zagórski, R., additional, Zaniol, B., additional, Zaupa, M., additional, Zella, D., additional, Zerbetto, E., additional, Zucchetti, S., additional, Zuin, E., additional, and Serianni, G., additional

Published
2024
Full Text
View/download PDF

8. Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia

Author

Sambri, I, Massa, F, Gullo, F, Meneghini, S, Cassina, L, Carraro, M, Dina, G, Quattrini, A, Patanella, L, Carissimo, A, Iuliano, A, Santorelli, F, Codazzi, F, Grohovaz, F, Bernardi, P, Becchetti, A, Casari, G, Sambri I., Massa F., Gullo F., Meneghini S., Cassina L., Carraro M., Dina G., Quattrini A., Patanella L., Carissimo A., Iuliano A., Santorelli F., Codazzi F., Grohovaz F., Bernardi P., Becchetti A., Casari G., Sambri, I, Massa, F, Gullo, F, Meneghini, S, Cassina, L, Carraro, M, Dina, G, Quattrini, A, Patanella, L, Carissimo, A, Iuliano, A, Santorelli, F, Codazzi, F, Grohovaz, F, Bernardi, P, Becchetti, A, Casari, G, Sambri I., Massa F., Gullo F., Meneghini S., Cassina L., Carraro M., Dina G., Quattrini A., Patanella L., Carissimo A., Iuliano A., Santorelli F., Codazzi F., Grohovaz F., Bernardi P., Becchetti A., and Casari G.

Abstract

Background: Mutations of the mitochondrial protein paraplegin cause hereditary spastic paraplegia type 7 (SPG7), a so-far untreatable degenerative disease of the upper motoneuron with still undefined pathomechanism. The intermittent mitochondrial permeability transition pore (mPTP) opening, called flickering, is an essential process that operates to maintain mitochondrial homeostasis by reducing intra-matrix Ca2+ and reactive oxygen species (ROS) concentration, and is critical for efficient synaptic function. Methods: We use a fluorescence-based approach to measure mPTP flickering in living cells and biochemical and molecular biology techniques to dissect the pathogenic mechanism of SPG7. In the SPG7 animal model we evaluate the potential improvement of the motor defect, neuroinflammation and neurodegeneration by means of an mPTP inducer, the benzodiazepine Bz-423. Findings: We demonstrate that paraplegin is required for efficient transient opening of the mPTP, that is impaired in both SPG7 patients-derived fibroblasts and primary neurons from Spg7−/− mice. We show that dysregulation of mPTP opening at the pre-synaptic terminal impairs neurotransmitter release leading to ineffective synaptic transmission. Lack of paraplegin impairs mPTP flickering by a mechanism involving increased expression and activity of sirtuin3, which promotes deacetylation of cyclophilin D, thus hampering mPTP opening. Pharmacological treatment with Bz-423, which bypasses the activity of CypD, normalizes synaptic transmission and rescues the motor impairment of the SPG7 mouse model. Interpretation: mPTP targeting opens a new avenue for the potential therapy of this form of spastic paraplegia. Funding: Telethon Foundation grant (TGMGCSBX16TT); Dept. of Defense, US Army, grant W81XWH-18–1–0001

Published
2020

9. Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)

Author

Elli, E, Iurlo, A, Aroldi, A, Caramella, M, Malato, S, Casartelli, E, Maffioli, M, Gardellini, A, Carraro, M, D'Adda, M, Polverelli, N, Rossi, M, Orofino, N, Carrer, A, Gambacorti-Passerini, C, Antolini, L, Passamonti, F, Elli E. M., Iurlo A., Aroldi A., Caramella M., Malato S., Casartelli E., Maffioli M., Gardellini A., Carraro M. C., D'Adda M., Polverelli N., Rossi M., Orofino N., Carrer A., Gambacorti-Passerini C., Antolini L., Passamonti F., Elli, E, Iurlo, A, Aroldi, A, Caramella, M, Malato, S, Casartelli, E, Maffioli, M, Gardellini, A, Carraro, M, D'Adda, M, Polverelli, N, Rossi, M, Orofino, N, Carrer, A, Gambacorti-Passerini, C, Antolini, L, Passamonti, F, Elli E. M., Iurlo A., Aroldi A., Caramella M., Malato S., Casartelli E., Maffioli M., Gardellini A., Carraro M. C., D'Adda M., Polverelli N., Rossi M., Orofino N., Carrer A., Gambacorti-Passerini C., Antolini L., and Passamonti F.

Published
2019

10. Validare le pratiche collaborative per l’economia circolare urbana: il punto di vista del design

Author

De Salvo, V., Carraro, M., Bianchini, M., Maffei, S., De Salvo, Veronica, Carraro, Michelangelo, Bianchini, Massimo, and Maffei, Stefano

Subjects
Urban circular economy, Validation, Theory of change, Coproduction, Settore ICAR/13 - Disegno Industriale
Abstract

The article presents the results of the research activity carried out within the framework of the European project H2020 REFLOW, which aims to build an integrated approach for the development of innovative participatory practices dedicated to urban circular metabolisms. As a result of the survey conducted on the application of collaborative models for the urban circular economy, it emerged that there is no shared operational strategy that can be adopted for the circular development of complex systems, such as cities. Based on this premise, this paper offers a new perspective on how to build and validate a transitional pathway for the development of circular cities through the adoption of a design-oriented approach that orchestrates different resources and capacities.

Published
2021

11. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

Author

Pungolino, E, D'Adda, M, De Canal, G, Trojani, A, Perego, A, Elena, C, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Artale, S, Anghilieri, M, Molteni, A, Caramella, M, Baruzzo, G, Nichelatti, M, Di Camillo, B, Cairoli, R, Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, Cairoli R, Pungolino, E, D'Adda, M, De Canal, G, Trojani, A, Perego, A, Elena, C, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Artale, S, Anghilieri, M, Molteni, A, Caramella, M, Baruzzo, G, Nichelatti, M, Di Camillo, B, Cairoli, R, Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, and Cairoli R

Abstract

Chronic Myeloid Leukemia is a clonal disorder characterized by the presence of the Ph-chromosome and the BCR-ABL tyrosine-kinase (TK). Target-therapy with Imatinib has greatly improved its outcome. Deeper and faster responses are reported with the second-generation TKI Nilotinib. Sustained responses may enable TKI discontinuation. However, even in a complete molecular response, some patients experience disease recurrence possibly due to persistence of quiescent leukemic CD34+/lin−Ph+ stem cells (LSCs). Degree and mechanisms of LSCs clearance during TKI treatment are not clearly established. The PhilosoPhi34 study was designed to verify the in-vivo activity and timecourse of first-line Nilotinib therapy on BM CD34+/lin−Ph+ cells clearance. Eighty-seven CP-CML patients were enrolled. BM cells were collected and tested for Ph+ residual cells, at diagnosis, 3, 6 and 12 months of treatment. FISH analysis of unstimulated CD34+/lin− cells in CCyR patients were positive in 8/65 (12.3%), 5/71 (7%), 0/69 (0%) evaluable tests, respectively. Per-Protocol analysis response rates were as follows: CCyR 95% at 12 months, MR4.5 31% and 46% at 12 and 36 months, respectively. An exploratory Gene Expression Profiling (GEP) study of CD34+/lin− cells was performed on 30 patients at diagnosis and after, on 79 patients at diagnosis vs 12 months of nilotinib treatment vs 10 healthy subjects. Data demonstrated some genes significantly different expressed: NFKBIA, many cell cycle genes, ABC transporters, JAK-STAT signaling pathway (JAK2). In addition, a correlation between different expression of some genes (JAK2, OLFM4, ICAM1, NFKBIA) among patients at diagnosis and their achievement of an early and deeper MR was observed.

Published
2021

14. Nilotinib induced bone marrow CD34+/lin–Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

Author

Pungolino, E, Rossi, G, De Canal, G, Trojani, A, D'Adda, M, Perego, A, Orlandi, E, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Lodola, M, Artale, S, Anghilieri, M, Spedini, P, Cantoni, S, Di Camillo, B, Morra, E, Cairoli, R, Pungolino E., Rossi G., De Canal G., Trojani A., D'adda M., Perego A., Orlandi E. M., Lunghi F., Turrini M., Borin L., Iurlo A., Latargia M. L., Carraro M. C., Spina F., Lodola M., Artale S., Anghilieri M., Spedini P., Cantoni S., Di Camillo B., Morra E., Cairoli R., Pungolino, E, Rossi, G, De Canal, G, Trojani, A, D'Adda, M, Perego, A, Orlandi, E, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Lodola, M, Artale, S, Anghilieri, M, Spedini, P, Cantoni, S, Di Camillo, B, Morra, E, Cairoli, R, Pungolino E., Rossi G., De Canal G., Trojani A., D'adda M., Perego A., Orlandi E. M., Lunghi F., Turrini M., Borin L., Iurlo A., Latargia M. L., Carraro M. C., Spina F., Lodola M., Artale S., Anghilieri M., Spedini P., Cantoni S., Di Camillo B., Morra E., and Cairoli R.

Published
2018

15. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Author

Pioltelli, M, Pungolino, E, D'Adda, M, Elena, C, Borin, L, Perego, A, Malato, S, Spina, F, Artale, S, Carraro, M, Orofino, N, Anghilieri, M, Farina, M, Latargia, M, Iurlo, A, Trojani, A, Turrini, M, Caramella, M, Spedini, P, Rossi, G, Morra, E, Cairoli, R, Pioltelli ML, Pungolino E, D'adda M, Elena C, Borin LM, Perego A, Malato S, Spina F, Artale S, Carraro M, Orofino N, Anghilieri M, Farina M, Latargia ML, Iurlo A, Trojani A, Turrini M, Caramella M, Spedini P, Rossi G, Morra E, Cairoli R, Pioltelli, M, Pungolino, E, D'Adda, M, Elena, C, Borin, L, Perego, A, Malato, S, Spina, F, Artale, S, Carraro, M, Orofino, N, Anghilieri, M, Farina, M, Latargia, M, Iurlo, A, Trojani, A, Turrini, M, Caramella, M, Spedini, P, Rossi, G, Morra, E, Cairoli, R, Pioltelli ML, Pungolino E, D'adda M, Elena C, Borin LM, Perego A, Malato S, Spina F, Artale S, Carraro M, Orofino N, Anghilieri M, Farina M, Latargia ML, Iurlo A, Trojani A, Turrini M, Caramella M, Spedini P, Rossi G, Morra E, and Cairoli R

Published
2018

16. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino, E, D'Adda, M, Trojani, A, Perego, D, Pioltelli, M, Rossi, G, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Lodola, M, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego D, Pioltelli ML, Rossi G, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Lodola M, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro M, Di Camillo B, Gramegna D, Morra E, Cairoli R, Pungolino, E, D'Adda, M, Trojani, A, Perego, D, Pioltelli, M, Rossi, G, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Lodola, M, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego D, Pioltelli ML, Rossi G, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Lodola M, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro M, Di Camillo B, Gramegna D, Morra E, and Cairoli R

Published
2018

18. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Author

Steingo, B. Al Malik, Y. Bass, A.D. Berkovich, R. Carraro, M. Fernández, Ó. Ionete, C. Massacesi, L. Meuth, S.G. Mitsikostas, D.D. Pardo, G. Simm, R.F. Traboulsee, A. Choudhry, Z. Daizadeh, N. Compston, D.A.S. the CAMMS223, CAMMS03409, TOPAZ Investigators

Abstract

Background: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing–remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS223 patients who enrolled in the CAMMS03409 extension (NCT00930553), with available follow-up through the subsequent TOPAZ extension (NCT02255656). Methods: In CAMMS223, patients received 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days); 22% received a third course. In the open-label, nonrandomized extensions, patients could receive as-needed additional alemtuzumab or other disease-modifying therapies. Results: Of 108 alemtuzumab-treated patients in CAMMS223, 60 entered the CAMMS03409 extension; 33% received a total of 2 alemtuzumab courses, and 73% received no more than 3 courses through Year 12. Over 12 years, annualized relapse rate was 0.09, 71% of patients had stable or improved Expanded Disability Status Scale scores, and 69% were free of 6-month confirmed disability worsening. In Year 12, 73% of patients were free of MRI disease activity. Cumulatively throughout the extensions (Years 7–12), 34% of patients had no evidence of disease activity. Adverse event (AE) incidence declined through Year 12. Infusion-associated reactions peaked at first course and declined thereafter. Cumulative thyroid AE incidence was 50%; one immune thrombocytopenia event occurred, and there were no autoimmune nephropathy cases. Conclusions: Alemtuzumab efficacy was maintained over 12 years in CAMMS223 patients, with 73% receiving no more than three courses. The safety profile in this cohort was consistent with other alemtuzumab clinical trials. © 2020, The Author(s).

Published
2020

19. Método de Folin Ciocalteau adaptado para quantificar polifenóis em extratos de erva-mate

Author

LAZZAROTTO, S. R. da S., SCHERRUTH, M. S. de F., CALIXTO, P. S., CARRARO, M. de M., SILVEIRA, A. C. da, LAZZAROTTO, M., SIMONE ROSA DA SILVEIRA LAZZAROTTO, Doutoranda na UEPG, MARIELLY STASYSZEN DE FREITAS SCHERRUTH, FAPAR, PATRICIA STHEFANI CALIXTO, Mestranda na UFPR, MATHEUS DE MELO CARRARO, Graduanda da UEPG, ANA CLAUDIA DA SILVEIRA, Estagiária de pós-graduação na Embrapa Florestas, and MARCELO LAZZAROTTO, CNPF.

Subjects
Erva mate, Polifenois, Planejamento experimental, Method adaptation, Experimental planning, Polyphenols, Cinética de reação, Ilex Paraguariensis, Reaction kinetics, Adaptação de metodologia
Abstract

A folha de erva-mate é consumida tradicionalmente e conhecida pela alta concentração de polifenóis. O método espectrofotométrico comumente usado para determinar o Teor de Polifenóis Totais (CFT) é o Folin-Ciocalteu. O objetivo desse trabalho foi adaptar o método de Folin-Ciocalteau para determinar o CTF em extrato de erva-mate visando a redução do tempo de reação, proporcionando eficiência e economia. Para tanto, a cinética da reação envolvida na análise do extrato de erva-mate foi estudada, sendo observada uma mudança de inclinação da curva cinética em 30 minutos de reação. Para avaliar a adequação do tempo de reação da análise em 30 minutos, a curva padrão foi obtida por três analistas diferentes e os resultados comparados à análise utilizando tempo de reação de 2 horas, conforme método Folin-Ciocalteu. Os resultados foram expressos em equivalente de ácido gálico (EAG). Os resultados de absorbância variaram de 0,004 ± 0,004 (0 mg EAG L-1)a 1,187 ± 0,100 (1000 mg EAG L-1) para a reação de 2 horas. Na reação de 30 minutos estes valores variaram de 0,005 ± 0,004 (0 mg EAG L-1) a 1,197 ± 0,022 (1000 mg EAG L-1). Estes métodos foram utilizados para quantificar o CFT em folhas de erva-mate e osresultados foram de 58,33 ± 3,90 mg EAG g-1(método tradicional) e de 57,77 ± 2,70 mg EAG g-1(método adaptado). Estes resultados demonstram a reprodutibilidade no método adaptado, mostrando a sua utilidade para obter maior eficiência e economia na análise. Made available in DSpace on 2021-04-23T12:34:14Z (GMT). No. of bitstreams: 1 Marcelo-Lazzarotto-Metodo-de-Folin.pdf: 534522 bytes, checksum: 8c266ba044c4d5166c536936dac6665a (MD5) Previous issue date: 2020

Published
2020

22. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Author

Gemelli, M, Elli, E, Elena, C, Iurlo, A, Intermesoli, T, Maffioli, M, Pungolino, E, Carraro, M, D'Adda, M, Lunghi, F, Anghileri, M, Polverelli, N, Rossi, M, Bacciocchi, M, Bono, E, Bucelli, C, Passamonti, F, Antolini, L, Passerini, C, Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D'Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, Passerini, Carlo Gambacorti, Gemelli, M, Elli, E, Elena, C, Iurlo, A, Intermesoli, T, Maffioli, M, Pungolino, E, Carraro, M, D'Adda, M, Lunghi, F, Anghileri, M, Polverelli, N, Rossi, M, Bacciocchi, M, Bono, E, Bucelli, C, Passamonti, F, Antolini, L, Passerini, C, Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D'Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, and Passerini, Carlo Gambacorti

Abstract

Background Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic formulations are contrasting. The aim of this study was to investigate the safety and efficacy of generic imatinib in CML patients treated in 12 Italian institutes. Methods This is an observational, retro-prospective analysis of patients with CML for whom the treatment was switched from brand to generic imatinib. We analyzed and compared the variation in quantitative PCR values before and after the switch, and the proportion of patients who maintained molecular response after changing from brand to generic imatinib. Adverse events (AEs) were also evaluated. Results Two hundred patients were enrolled. The median PCR value after the switch was reduced by 0.25 compared to the values before the switch. A significant difference was found between median PCR values before and after the switch in favor of generic imatinib (P = 0.003). Molecular responses remained stable in 69.0%, improved in 25.5%, and worsened in 5.5% of patients. AEs were similar in the pre- and post-switch periods; however, a significant difference was found in favor of generic imatinib for muscular cramps (P < 0.0001), periorbital edema (P=0.0028), edema of the limbs (P <0.0001), fatigue (P =0.0482), and diarrhea (P=0.0027). Conclusion Our data indicate that generic imatinib does not have deleterious effects on CML control and present an acceptable safety profile, similar or better than brand imatinib.

Published
2020

24. Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension

Author

VAN WIJMEERSCH, Bart, Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Melanson, M., Jacobs, Alessia, Wiendl, H., VAN WIJMEERSCH, Bart, Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Melanson, M., Jacobs, Alessia, and Wiendl, H.

Subjects
parasitic diseases, virus diseases, equipment and supplies
Abstract

Sanofi; Bayer HealthCare Pharmaceuticals

Published
2018

25. P6547The energy cost of His bundle pacing can be curtailed

Author

Zanon, F, primary, Marcantoni, L, additional, Pastore, G, additional, Baracca, E, additional, Picariello, C, additional, Lanza, D, additional, Maddalozzo, A, additional, Giatti, S, additional, Carraro, M, additional, Roncon, L, additional, Barbetta, A, additional, and Di Gregorio, F, additional

Published
2019
Full Text
View/download PDF

27. PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION

Author

Pungolino, E, D'Adda, M, Trojani, A, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Bossi, L, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Pioltelli, M, Rossi, G, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Bossi LE, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro MC, Di Camillo B, Gramegna D, Pioltelli ML, Rossi G, Morra E, Cairoli R, Pungolino, E, D'Adda, M, Trojani, A, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Bossi, L, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Pioltelli, M, Rossi, G, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Bossi LE, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro MC, Di Camillo B, Gramegna D, Pioltelli ML, Rossi G, Morra E, and Cairoli R

Published
2019

28. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

Author

Trojani, A, Pungolino, E, Dal Molin, A, Bossi, L, Rossi, G, D'Adda, M, Perego, A, Elena, C, Turrini, M, Borin, L, Bucelli, C, Malato, S, Carraro, M, Spina, F, Latargia, M, Artale, S, Spedini, P, Anghilieri, M, Di Camillo, B, Baruzzo, G, De Canal, G, Iurlo, A, Morra, E, Cairoli, R, Trojani A, Pungolino E, Dal Molin A, Bossi LE, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R, Trojani, A, Pungolino, E, Dal Molin, A, Bossi, L, Rossi, G, D'Adda, M, Perego, A, Elena, C, Turrini, M, Borin, L, Bucelli, C, Malato, S, Carraro, M, Spina, F, Latargia, M, Artale, S, Spedini, P, Anghilieri, M, Di Camillo, B, Baruzzo, G, De Canal, G, Iurlo, A, Morra, E, Cairoli, R, Trojani A, Pungolino E, Dal Molin A, Bossi LE, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, and Cairoli R

Published
2019

29. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Author

Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Bossi, L, Baruzzo, G, Di Camillo, B, Perego, A, Turrini, M, Elena, C, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, M, Spedini, P, Artale, S, Anghilieri, M, Carraro, M, Bucelli, C, De Canal, G, Morra, E, Cairoli, R, Trojani A., Pungolino E., Rossi G., D'Adda M., Bossi L.E., Baruzzo G., Di Camillo B., Perego A., Turrini M., Elena C., Borin L.M., Iurlo A., Malato S., Spina F., Latargia M.L., Spedini P., Artale S., Anghilieri M., Carraro M.C., Bucelli C., De Canal G., Morra E., Cairoli R, Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Bossi, L, Baruzzo, G, Di Camillo, B, Perego, A, Turrini, M, Elena, C, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, M, Spedini, P, Artale, S, Anghilieri, M, Carraro, M, Bucelli, C, De Canal, G, Morra, E, Cairoli, R, Trojani A., Pungolino E., Rossi G., D'Adda M., Bossi L.E., Baruzzo G., Di Camillo B., Perego A., Turrini M., Elena C., Borin L.M., Iurlo A., Malato S., Spina F., Latargia M.L., Spedini P., Artale S., Anghilieri M., Carraro M.C., Bucelli C., De Canal G., Morra E., and Cairoli R

Published
2019

30. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino E, D'adda M, Trojani A, Perego D, Pioltelli ML, Rossi G, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Lodola M, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro M, Di Camillo B, Gramegna D, Morra E, Cairoli R, Pungolino, E, D'Adda, M, Trojani, A, Perego, D, Pioltelli, M, Rossi, G, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Lodola, M, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Morra, E, and Cairoli, R

Subjects
Janus kinase 2, biology, business.industry, Immunology, NFKBIA Gene, Myeloid leukemia, Cell Biology, Hematology, NFKB1, Biochemistry, Gene expression profiling, medicine.anatomical_structure, Nilotinib, Molecular Response, Cancer research, biology.protein, Medicine, Bone marrow, business, medicine.drug
Abstract

Background Targeted therapy with Tyrosine-Kinase-Inhibitors (TKIs) totally modified the course of treatment of Chronic Myeloid Leukemia (CML). The objectives and the needs of treatment have been modified during the last years and the discontinuation of therapy is now a feasible aim. However, a lot of biological data acquired in the last twenty years, showed that degree and mechanisms of Leukemic Stem Cells (LSCs) clearance during TKI treatment are not clearly established as well as the predictive criteria for a stable and prolonged Treatment Free Remission (TFR). The multicentre, prospective, single-arm PhilosoPhi34 study (EudraCT: 2012-005062-34) was designed by the Rete Ematologica Lombarda (REL), to verify the in-vivo activity and time-course of first-line Nilotinib (NIL) therapy on Bone Marrow (BM) CD34+/lin-Ph+ cells clearance. An exploratory Gene Expression Profiling (GEP) study of CD34+/lin- cells at diagnosis and at 12 months (mos) of treatment, for the first 30 evaluable pts, was included. Preliminary GEP data suggested a correlation between different NFKBIA expression at diagnosis and at 12 mos and the achievement of a deeper Molecular Response (MR) (Pungolino et al, AJH 2018). We report here some results of GEP analysis on all enrolled evaluable pts and their possible correlation with clinical data. Methods BM cells were collected and stored at diagnosis and at 12 mos of treatment. CD34+/lin- cells were purified with a Diamond CD34 Isolation Kit Miltenyi (97% of purity). For GEP analysis we used Affymetrix HG-U133 Plus 2.0 microarray and Genechip platform (Affymetrix) and the Affymetrix GeneChip Scanner 3000. Data was pre-processed and normalized using the Robust Multi-array Average (RMA) algorithm. The Significant Analysis of Microarrays (SAM) was used to identify genes with statistically significant changes in expression. P-values were corrected for multiple testing using false discovery rate, for differentially expressed genes confirmation. We chose to analyse different expression of NFKBIA (the inhibitor of NF-kB onco-gene) in order to confirm the preliminary data reported on the first 30 analysed pts. Pts were monitored according to ELN-recommendation. Biological data were correlated with MR at 3, 12 and 36 mos of therapy. We use Fishers test to compare unbalanced group. Results Out of the 87 enrolled pts, 80 completed the first 12 mos of treatment and 78 (1 failure and 77 CCyR) were evaluable for GEP analysis. We observed 2726 genes symbol differentially expressed of which 1868 are coding genes. Among these, JAK-2 showed a down regulation at 12 mos (p: .024). JAK-2 expression ranged from 2.62 to 4.95 at diagnosis and from 1.48 to 5.58 at 12 mos. Only 26/78 pts increased JAK-2 expression that was > 4 in 1/26 pts, at diagnosis; 2/26 (7.69%) pts showed a H Sokal. Other 52/78 pts decreased JAK-2 expression that was ≥ 4 in 21/52 pts, at diagnosis; 10/52 (19.23%) pts and 6/21 (28,57%) pts showed a H Sokal. Similarly, when we compared low JAK-2 expression (< 3.5) vs vary high expression (≥ 4) 2/21 vs 6/22 pts had H Sokal (9.52% vs 27.27%; p: .0057). Considering the role of JAK-2 and NFKBIA in cell regulation and survival, we evaluated how the combination of their different expression impact on MR (i.e. NFKBIA increased expression/JAK-2 decreased expression vs NFKBIA decreased expression/JAK-2 increased expression). Data are reported in Table 1 and 2. Conclusion GEP analysis showed a down regulation of JAK-2 expression after 12 mos of first line NIL treatment, in 78 early chronic phase CML pts. Data suggest that high expression of JAK-2, at diagnosis, correlate with H Sokal score. However, H Sokal pts with a JAK-2 down regulation, obtain during treatment similar MR compared to L Sokal pts. Additionally, the study confirms our preliminary observation on 30 pts , concerning the role of NKBIA up - regulation in increasing percentage of earlier and deeper MR . The better condition of NFKBIA and JAK-2 expression (up regulation of NFKBIA and down regulation of JAK-2) is associated with a higher percentage of early MR3 and optimal responses over time, despite the higher number of H Sokal pts in this group. A study with NIL as first line treatment combined with low dose of JAK-2 inhibitor and a natural inhibitor of NF-kB (such as curcuma), during the first year of treatment, to increase the deeper MR rate and the probability of TFR is warrented. Disclosures Rossi: Sandoz: Honoraria; Jazz: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria; Teva: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Honoraria; Novartis: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees.

Published
2018
Full Text
View/download PDF

31. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial

Author

Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, Moccetti T, Rossi MG, AnesiniA A, Allemano P, Reynaud SG, Fenoil R, Giannuzzi P, Corrà U, Gavazzi A, Grosu A, Volpi A, Jones KN, Lissi C, Turazza FM, Frigerio M, Febo O, Olmett F, Cirò A, Vincenzi A, Scelsi L, Campana C, Opasich C, Gualco A, Iannone MA, Cucchi G, Catania G, Tarantini L, Rigatelli G, Boni S, Carlon R, Sacchetta A, Borgese L, Sarto P, Milan S, Milan D, Roncon L, Carraro M, Rossi R, Carbonieri E, Valentini A, Brighetti G, Cantarelli A, Ferrari R, FuciliF A, Bonfiglioli A, Mariani PR, Martinelli S, Buccolieri M, Moretti L, Partemi L, Gregori G, Testa D, Pulignano G, Santini M, Varveri A, Aspromonte N, Staniscia D, Calgione E, Vetrano A, Pettinati G, Ciricugno S, Gualtieri MR, Villella M, Lauletta R, Tagliamonte E, Scozzafava A, Cassano S, Misuraca G, Caporale R, Musca G, Carpino C, Leonardi G, Ledda G, Di Tano G, Cirrincione V, Sanfilippo N, Enia F, Floresta M, Porcu M, Orrù P., PERRONE FILARDI, PASQUALE, Røsjø, H, Masson, S, Latini, R, Flyvbjerg, A, Milani, V, La Rovere, Mt, Revera, M, Mezzani, A, Tognoni, G, Tavazzi, L, Omland, T, Moccetti, T, Rossi, Mg, Anesinia, A, Allemano, P, Reynaud, Sg, Fenoil, R, Giannuzzi, P, Corrà, U, Gavazzi, A, Grosu, A, Volpi, A, Jones, Kn, Lissi, C, Turazza, Fm, Frigerio, M, Febo, O, Olmett, F, Cirò, A, Vincenzi, A, Scelsi, L, Campana, C, Opasich, C, Gualco, A, Iannone, Ma, Cucchi, G, Catania, G, Tarantini, L, Rigatelli, G, Boni, S, Carlon, R, Sacchetta, A, Borgese, L, Sarto, P, Milan, S, Milan, D, Roncon, L, Carraro, M, Rossi, R, Carbonieri, E, Valentini, A, Brighetti, G, Cantarelli, A, Ferrari, R, Fucilif, A, Bonfiglioli, A, Mariani, Pr, Martinelli, S, Buccolieri, M, Moretti, L, Partemi, L, Gregori, G, Testa, D, Pulignano, G, Santini, M, Varveri, A, Aspromonte, N, Staniscia, D, Calgione, E, Vetrano, A, PERRONE FILARDI, Pasquale, Pettinati, G, Ciricugno, S, Gualtieri, Mr, Villella, M, Lauletta, R, Tagliamonte, E, Scozzafava, A, Cassano, S, Misuraca, G, Caporale, R, Musca, G, Carpino, C, Leonardi, G, Ledda, G, Di Tano, G, Cirrincione, V, Sanfilippo, N, Enia, F, Floresta, M, Porcu, M, and Orrù, P.

Subjects
Male, endocrine system, medicine.medical_specialty, Randomization, Renal function, Gastroenterology, law.invention, Randomized controlled trial, law, Diabetes mellitus, Internal medicine, Humans, Medicine, Heart rate variability, Rosuvastatin, Aged, Aged, 80 and over, Heart Failure, biology, business.industry, Chromogranin A, Middle Aged, Prognosis, medicine.disease, Endocrinology, Heart failure, Chronic Disease, biology.protein, Female, Cardiology and Cardiovascular Medicine, business, Biomarkers, medicine.drug
Abstract

Udgivelsesdato: 2010 AIMS: To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). METHODS AND RESULTS: Plasma CgA levels were measured at randomization and after 3 months in 1233 patients (median age 68 years, 80% male) with chronic, stable HF from the GISSI-HF trial. Circulating CgA levels were associated with several established risk markers in HF, including increased age, diabetes, reduced renal function, and heart rate variability. During a median follow-up of 3.9 years, 333 patients (27%) died. By univariable analysis, plasma CgA levels at baseline were strongly associated with all-cause mortality during follow-up; 2nd vs. 1st tertile: HR 1.58 (1.17-2.11), P = 0.002; and 3rd vs. 1st tertile: HR 2.35 (1.78-3.10), P < 0.0001. After adjustment for established risk factors of mortality, this association was attenuated and no longer significant. Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin did not significantly change plasma CgA concentration over 3 months. CONCLUSION: Measurement of circulating CgA levels in patients with chronic, stable HF does not provide incremental prognostic information to that obtained from physical examination, routine biochemical analysis, and contemporary HF biomarkers.

Published
2010
Full Text
View/download PDF

36. 43Hisian pacing with apical back-up on demand is safe and effective

Author

Zanon, F, primary, Marcantoni, L, additional, Pastore, G, additional, Baracca, E, additional, Picariello, C, additional, Lanza, D, additional, Giatti, S, additional, Aggio, S, additional, Carraro, M, additional, Conte, L, additional, D'elia, K, additional, Roncon, L, additional, Rinuncini, M, additional, and Galasso, M P, additional

Published
2018
Full Text
View/download PDF

37. P1132LV lead apical placement could be the best option in selected patients candidate to CRT

Author

Zanon, F, primary, Marcantoni, L, additional, Baracca, E, additional, Pastore, G, additional, Giatti, S, additional, Aggio, S, additional, Picariello, C, additional, Lanza, D, additional, Roncon, L, additional, Noventa, F, additional, Conte, L, additional, Carraro, M, additional, Rinuncini, M, additional, Galasso, M P, additional, and D'elia, K, additional

Published
2018
Full Text
View/download PDF

38. P411His pacing improved ejection fraction on long term follow-up in the subgroup of patients with low ejection fraction at implant

Author

Zanon, F, primary, Marcantoni, L, additional, Pastore, G, additional, Giatti, S, additional, Baracca, E, additional, Aggio, S, additional, Picariello, C, additional, Roncon, L, additional, Conte, L, additional, Lanza, D, additional, D' Elia, K, additional, Carraro, M, additional, Galasso, M P, additional, and Rinuncini, M, additional

Published
2018
Full Text
View/download PDF

39. 42His bundle pacing in BBB patients: outcomes over a long-term follow-up

Author

Zanon, F, primary, Marcantoni, L, additional, Pastore, G, additional, Baracca, E, additional, Aggio, S, additional, Carraro, M, additional, Picariello, C, additional, Lanza, D, additional, Giatti, S, additional, Rinuncini, M, additional, Galasso, M P, additional, D'elia, K, additional, Roncon, L, additional, and Conte, L, additional

Published
2018
Full Text
View/download PDF

40. Role of Frailty Components on Quality of Life in Dialysis Patients. A Cross-sectional Study

Author

Sclauzero, P., Galli, G., Carraro, M., Barbati, G., Panzetta, G.O., Sclauzero, P., Galli, G., Carraro, M., Barbati, G., and Panzetta, G.O.

Abstract

Most of dialysis patients present components of frailty: comorbidities, disabilities, dependence, malnutrition, cognitive impairment, and poor social conditions. Frailty is suspected to affect the quality of life (QoL) of dialysis patients. This study aims to evaluate this relation. Little is available in the Literature on this topic. We enrolled 203 out of 233 prevalent dialysis patients in the Trieste area. We administered to them the Short-Form 36 (SF-36) questionnaire, applied Activities of Daily Living, Instrumental Activities of Daily Living, Subjective Global Assessment scales, Karnofsky Index, and analyzed their social conditions. Patients (126 males) had a mean age of 72.03+11.9 years, and a dialytic age of 42.6+55.6 months. The physical component of QoL (39.3+10.4) is more compromised than the mental one that is 48.5+8.6 (0–100 scale). Dependence (p<0.001), malnutrition (p=0.001) and disability (p=0.005) had a negative role on many domains of SF-36. Linear regression analysis excluded comorbidities, even significant at an univariate analysis (data adjusted for gender, age and age in dialysis). Living with family (p=0.002), good economic conditions (p=0.01), and, above all, social relationships (p<0.001) were significantly related with a better QoL (test ANOVA). Constant screening of patients, nutritional and functional rehabilitation, prevention of social isolation through social and health services are indispensable to guarantee a satisfactory QoL. (sian) (nursing), I pazienti in dialisi presentano spesso diverse componenti della fragilità: comorbidità, disabilità, dipendenza, malnutrizione, deficit cognitivo, inadeguate condizioni sociali, che incidono sulla qualità di vita (QoL). Scopo del lavoro è stato indagare questa relazione essendo la letteratura ancora non conclusiva. Ai 203 pazienti (età media 72.03+11.9 aa; età dialitica 42.6+55.6 mm; 126 m) in dialisi a Trieste l'1 agosto 2010 sono stati misurati: QoL (SF-36), disabilità (scale ADL e IADL), dipendenza (Karnofsky Index), stato nutrizionale (scala SGA) ed analizzato lo stato sociale. Il cluster componente fisica SF-36 (39.3+10.4) è risultato più compromesso di quello mentale: 48.5+8.6 (scala 0–100). I pazienti hanno presentato disabilità fisiche (ADL: 32.5%), strumentali (IADL: 38.4%), malnutrizione (34%), dipendenza (42.9%) e mediamente 3.04 comorbidità (range: 0–8). Il 31.5% vive senza supporto familiare, il 44.5% presenta ridotte relazioni sociali. La regressione lineare multipla ha dimostrato l'effetto negativo di: dipendenza (p<0.001), malnutrizione (p=0.001) e disabilità (p=0.005), escludendo comorbidità significative all'analisi univariata (dati aggiustati per genere, età, età dialitica). La vita in famiglia (p=0.002), il benessere economico (p=0.01) e soprattutto estese relazioni sociali (p<0.001) hanno avuto un ruolo positivo (test ANOVA). Pertanto una QoL soddisfacente è favorita dallo screening precoce, dalla riabilitazione funzionale-nutrizionale e dalla prevenzione dell'isolamento sociale attraverso una rete socio-sanitaria coordinata. (sian) (nursing)

Published
2018

41. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Author

Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Di Camillo, B, Perego, A, Turrini, M, Orlandi, E, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, M, Lanza, F, Artale, S, Anghilieri, M, Carraro, M, De Canal, G, Morra, E, Cairoli, R, Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Di Camillo B, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, De Canal G, Morra E, Cairoli R, Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Di Camillo, B, Perego, A, Turrini, M, Orlandi, E, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, M, Lanza, F, Artale, S, Anghilieri, M, Carraro, M, De Canal, G, Morra, E, Cairoli, R, Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Di Camillo B, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, De Canal G, Morra E, and Cairoli R

Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin-cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions. METHODS:We selected and counted BM CD34+/lin- cells of 30 CML patients at diagnosis and during 3, 6 and 12 months of first-line nilotinib treatment. GEP was performed between CD34+/lin- cells of patients at diagnosis and the same patients after 12 months of nilotinib. RESULTS: The number of BM CD34+/lin- cells dramatically decreased after 3, 6 and 12 months of nilotinib. GEP detected 264 statistically significant differentially expressed genes at diagnosis vs. 12 months of nilotinib. Functional enrichment analysis revealed groups of genes belonging to 14 pathways differentially active during nilotinib treatment. CONCLUSIONS: In conclusion, lipid, glucose and sphingolipid metabolism, insulin resistance, complement and coagulation, platelet activation, cytoscheleton, cell adhesion, transport, B cell differentiation, RAS-signaling pathway, proliferation, growth factors, and apoptosis were significantly deregulated between CML patients at diagnosis and after 12 months of nilotinib.

Published
2018

42. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

Author

Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Di Camillo, B, Perego, A, Turrini, M, Orlandi, E, Borin, L, Iurlo, A, Bucelli, C, Malato, S, Spina, F, Latargia, M, Lanza, F, Artale, S, Anghilieri, M, Carraro, M, De Canal, G, Morra, E, Cairoli, R, Trojani A., Pungolino E., Rossi G., D'Adda M., Lodola M., Di Camillo B., Perego A., Turrini M., Orlandi E., Borin L., Iurlo A., Bucelli C., Malato S., Spina F., Latargia M.L., Lanza F., Artale S., Anghilieri M., Carraro M.C., De Canal G., Morra E., Cairoli R, Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Di Camillo, B, Perego, A, Turrini, M, Orlandi, E, Borin, L, Iurlo, A, Bucelli, C, Malato, S, Spina, F, Latargia, M, Lanza, F, Artale, S, Anghilieri, M, Carraro, M, De Canal, G, Morra, E, Cairoli, R, Trojani A., Pungolino E., Rossi G., D'Adda M., Lodola M., Di Camillo B., Perego A., Turrini M., Orlandi E., Borin L., Iurlo A., Bucelli C., Malato S., Spina F., Latargia M.L., Lanza F., Artale S., Anghilieri M., Carraro M.C., De Canal G., Morra E., and Cairoli R

Published
2018

43. Rad9/53BP1 protects stalled replication forks from degradation in Mec1/ATR-defective cells

Author

Villa, M, Bonetti, D, Carraro, M, Longhese, M, Longhese, Maria P, Villa, M, Bonetti, D, Carraro, M, Longhese, M, and Longhese, Maria P

Abstract

Nucleolytic processing by nucleases can be a relevant mechanism to allow repair/restart of stalled replication forks. However, nuclease action needs to be controlled to prevent overprocessing of damaged replication forks that can be detrimental to genome stability. The checkpoint protein Rad9/53BP1 is known to limit nucleolytic degradation (resection) of DNA double-strand breaks (DSBs) in both yeast and mammals. Here, we show that loss of the inhibition that Rad9 exerts on resection exacerbates the sensitivity to replication stress of Mec1/ATR-defective yeast cells by exposing stalled replication forks to Dna2-dependent degradation. This Rad9 protective function is independent of checkpoint activation and relies mainly on Rad9-Dpb11 interaction. We propose that Rad9/53BP1 supports cell viability by protecting stalled replication forks from extensive resection when the intra-S checkpoint is not fully functional.

Published
2018

46. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial

Author

Dauriz, Marco, primary, Targher, Giovanni, additional, Temporelli, Pier Luigi, additional, Lucci, Donata, additional, Gonzini, Lucio, additional, Nicolosi, Gian Luigi, additional, Marchioli, Roberto, additional, Tognoni, Gianni, additional, Latini, Roberto, additional, Cosmi, Franco, additional, Tavazzi, Luigi, additional, Maggioni, Aldo Pietro, additional, Barlera, Simona, additional, Franzosi, Maria Grazia, additional, Maggioni, Aldo P., additional, Porcu, Maurizio, additional, Yusuf, Salim, additional, Camerini, Fulvio, additional, Cohn, Jay N., additional, Decarli, Adriano, additional, Pitt, Bertram, additional, Sleight, Peter, additional, Poole‐Wilson, Philip A., additional, Geraci, Enrico, additional, Scherillo, Marino, additional, Fabbri, Gianna, additional, Bartolomei, Barbara, additional, Bertoli, Daniele, additional, Cobelli, Franco, additional, Fresco, Claudio, additional, Ledda, Antonietta, additional, Levantesi, Giacomo, additional, Opasich, Cristina, additional, Rusconi, Franco, additional, Sinagra, Gianfranco, additional, Turazza, Fabio, additional, Volpi, Alberto, additional, Ceseri, Martina, additional, Alongi, Gianluca, additional, Atzori, Antonio, additional, Bambi, Filippo, additional, Bastarolo, Desiree, additional, Bianchini, Francesca, additional, Cangioli, Iacopo, additional, Canu, Vittoriana, additional, Caporusso, Concetta, additional, Cenni, Gabriele, additional, Cintelli, Laura, additional, Cocchio, Michele, additional, Confente, Alessia, additional, Fenicia, Eva, additional, Friso, Giorgio, additional, Gianfriddo, Marco, additional, Grilli, Gianluca, additional, Lazzaro, Beatrice, additional, Lonardo, Giuseppe, additional, Luise, Alessia, additional, Nota, Rachele, additional, Orlando, Mariaelena, additional, Petrolo, Rosaria, additional, Pierattini, Chiara, additional, Pierota, Valeria, additional, Provenzani, Alessandro, additional, Quartuccio, Velia, additional, Ragno, Anna, additional, Serio, Chiara, additional, Spolaor, Alvise, additional, Tafi, Arianna, additional, Tellaroli, Elisa, additional, Ghio, Stefano, additional, Ghizzardi, Elisa, additional, Masson, Serge, additional, Crociati, Lella, additional, La Rovere, Maria Teresa, additional, Corrà, Ugo, additional, Finzi, Andrea, additional, Gorini, Marco, additional, Milani, Valentina, additional, Orsini, Giampietro, additional, Bianchini, Elisa, additional, Cabiddu, Silvia, additional, Cangioli, Ilaria, additional, Cipressa, Laura, additional, Cipressa, Maria Lucia, additional, Di Bitetto, Giuseppina, additional, Ferri, Barbara, additional, Galbiati, Luisa, additional, Lorimer, Andrea, additional, Pera, Carla, additional, Priami, Paola, additional, Vasamì, Antonella, additional, Moccetti, T., additional, Rossi, M.G., additional, Pasotti, E., additional, Vaghi, F., additional, Roncarolo, P., additional, Zunino, M.T., additional, Matta, F., additional, Perinetto, E. Actis, additional, Gaita, F., additional, Azzaro, G., additional, Zanetta, M., additional, Paino, A.M., additional, Parravicini, U., additional, Vegis, D., additional, Conte, R., additional, Ferraro, P., additional, De Bernardi, A., additional, Morelloni, S., additional, Fagnani, M., additional, Lucchina, P. Greco, additional, Montagna, L., additional, Bellone, E., additional, Sappè, D., additional, Ferraro, F., additional, Delucchi, M., additional, Reynaud, S.G., additional, Dore, M., additional, La Brocca, A., additional, Massobrio, N., additional, Bo, L., additional, Trinchero, R., additional, Imazio, M., additional, Brocchi, G., additional, Nejrotti, A., additional, Rissone, L., additional, Gabasio, S., additional, Zocchi, C., additional, Randazzo, S., additional, Crenna, A., additional, Giannuzzi, P., additional, Bonanomi, E., additional, Mezzani, A., additional, De Marchi, M., additional, Begliuomini, G., additional, Gianonatti, C.A., additional, Gavazzi, A., additional, Grosu, A., additional, Dei Cas, L., additional, Nodari, S., additional, Garyfallidis, P., additional, Bertoletti, A., additional, Bonifazi, C., additional, Arisi, S., additional, Mascaro, F., additional, Fraccarollo, M., additional, Dell'Orto, S., additional, Sfolcini, M., additional, Bortolini, F., additional, Raccagni, D., additional, Turelli, A., additional, Santarone, M., additional, Miglierina, E., additional, Sormani, L., additional, Jemoli, R., additional, Tettamanti, F., additional, Pirelli, S., additional, Bianchi, C., additional, Verde, S., additional, Mariani, M., additional, Ziacchi, V., additional, Ferrazza, A., additional, Russo, A., additional, Bortolotti, M., additional, Pasini, G.F., additional, Volpi, A., additional, Jones, K.N., additional, Cuzzucrea, D., additional, Gullace, G., additional, Carbone, C., additional, Granata, A., additional, De Servi, S., additional, Del Rosso, G., additional, Inserra, C., additional, Renaldini, E., additional, Zappa, C., additional, Moretti, M., additional, Zanini, R., additional, Ferrari, M., additional, Moroni, E., additional, Cei, A., additional, Lissi, C., additional, Dovico, E., additional, Fiorentini, C., additional, Palermo, P., additional, Brusoni, B., additional, Negrini, M., additional, Heyman, J., additional, Danzi, G.B., additional, Finzi, A., additional, Frigerio, M., additional, Turazza, F., additional, Beretta, L., additional, Sachero, A., additional, Casazza, F., additional, Squadroni, L., additional, Lombardi, F., additional, Marano, L., additional, Margonato, A., additional, Fragasso, G., additional, Febo, O.C., additional, Aiolfi, E., additional, Olmetti, F., additional, Grieco, A., additional, Antonazzo, V., additional, Specchia, G., additional, Mortara, A., additional, Robustelli, F., additional, Songini, M.G., additional, Schweiger, C., additional, Frisinghelli, A., additional, Palvarini, M., additional, Campana, C., additional, Scelsi, L., additional, Ajmone Marsan, N., additional, Cobelli, F., additional, Gualco, A., additional, Opasich, C., additional, De Feo, S., additional, Mazzucco, R., additional, Iannone, M.A., additional, Diaco, T., additional, Zaniboni, D., additional, Milanesi, G., additional, Nassiacos, D., additional, Meloni, S., additional, Giani, P., additional, Nicoli, T., additional, Malinverni, C., additional, Gusmini, A., additional, Pozzoni, L., additional, Bisiani, G., additional, Margaroli, P., additional, Schizzarotto, A., additional, Daverio, A., additional, Occhi, G., additional, Partesana, N., additional, Bandini, P., additional, Rosella, M.G., additional, Giustiniani, S., additional, Cucchi, G., additional, Pedretti, R., additional, Raimondo, R., additional, Vaninetti, R., additional, Fedele, A., additional, Ghezzi, I., additional, Rezzonico, E., additional, Salerno Uriarte, J.A., additional, Morandi, F., additional, Salvucci, F., additional, Valenti, C., additional, Graziano, G., additional, Romanò, M., additional, Cimminiello, C., additional, Mangone, I., additional, Lombardo, M., additional, Quorso, P., additional, Marinoni, G., additional, Breghi, M., additional, Erckert, M., additional, Dienstl, A., additional, Mirante Marini, G., additional, Stefenelli, C., additional, Cioffi, G., additional, Buczkowska, E., additional, Bonanome, A., additional, Bazzanini, F., additional, Parissenti, L., additional, Serafini, C., additional, Catania, G., additional, Tarantini, L., additional, Rigatelli, G., additional, Boni, S., additional, Pasini, A., additional, Masini, E., additional, Zampiero, A.A., additional, Zanchetta, M., additional, Franceschetto, L., additional, Delise, P., additional, Marcon, C., additional, Sacchetta, A., additional, Borgese, L., additional, Artusi, L., additional, Casolino, P., additional, Corbara, F., additional, Banzato, A., additional, Barbiero, M., additional, Aldegheri, M.P., additional, Bazzucco, R., additional, Crivellenti, G., additional, Raviele, A., additional, Zanella, C., additional, Pascotto, P., additional, Sarto, P., additional, Milan, S., additional, Barbieri, E., additional, Girardi, P., additional, Dalla Villa, W., additional, Dalle Mule, J., additional, Di Sipio, M.L., additional, Cazzin, R., additional, Milan, D., additional, Zonzin, P., additional, Carraro, M., additional, Rossi, R., additional, Carbonieri, E., additional, Rossi, I., additional, Stritoni, P., additional, Meneghetti, P., additional, Risica, G., additional, Tenderini, P.L., additional, Vassanelli, C., additional, Zanolla, L., additional, Perini, G., additional, Brighetti, G., additional, Chiozza, R., additional, Giuliano, G., additional, Gortan, R., additional, Cesanelli, R., additional, Nicolosi, G.L., additional, Piazza, R., additional, Mos, L., additional, Vriz, O., additional, Pavan, D., additional, Pascottini, G., additional, Alberti, E., additional, Werren, M., additional, Solinas, L., additional, Sinagra, G., additional, Longaro, F., additional, Fioretti, P., additional, Albanese, M.C., additional, Miani, D., additional, Gianrossi, R., additional, Pende, A., additional, Rubartelli, P., additional, Magaia, O., additional, Domenicucci, S., additional, Caruso, D., additional, Faraguti, A.S., additional, Magliani, L., additional, Miccoli, F., additional, Guglielmino, G., additional, Bertoli, D., additional, Cantarelli, A., additional, Orlandi, S., additional, Vallebona, A., additional, Pozzati, A., additional, Brega, G., additional, Pancaldi, L.G., additional, Vandelli, R., additional, Urbinati, S., additional, Poci, M.G., additional, Zoli, M., additional, Costa, G.M., additional, Guiducci, U., additional, Zobbi, G., additional, Tartagni, F., additional, Tisselli, A., additional, Gentili, A., additional, Pieri, P., additional, Cagnetta, E., additional, Bendinelli, S., additional, Barbieri, A., additional, Conti, R., additional, Ferrari, R., additional, Merlini, F., additional, Fucili, A., additional, Moruzzi, P., additional, Buia, E., additional, Galvani, M., additional, Ferrini, D., additional, Baggioni, G., additional, Yiannacopulu, P., additional, Canè, G., additional, Bonfiglioli, A., additional, Zandomeneghi, R., additional, Brugioni, L., additional, Giannini, A., additional, Di Ruvo, R., additional, Giuliani, M., additional, Rusconi, L., additional, Del Corso, P., additional, Piovaccari, G., additional, Bologna, F., additional, Venturi, P., additional, Melandri, F., additional, Bagni, E., additional, Bolognese, L., additional, Perticucci, R., additional, Zuppiroli, A., additional, Nannini, M., additional, Consoli, N., additional, Petrone, P., additional, Pipitò, C., additional, Colombi, L., additional, Bernardi, D., additional, Mariani, P.R., additional, Testa, R., additional, Mazzinghi, F., additional, Cosmi, F., additional, Cosmi, D., additional, Zipoli, A., additional, Cecchi, A., additional, Castelli, G., additional, Ciaccheri, M., additional, Mori, F., additional, Pieri, F., additional, Valoti, P., additional, Chiarantini, D., additional, Santoro, G.M., additional, Minneci, C., additional, Marchi, F., additional, Milli, M., additional, Zambaldi, G., additional, Brandinelli Geri, A.A., additional, Cipriani, M., additional, Alessandri, M., additional, Severi, S., additional, Stefanelli, S., additional, Comella, A., additional, Poddighe, R., additional, Digiorgio, A., additional, Carluccio, M., additional, Berti, S., additional, Rizza, A., additional, Bonatti, V., additional, Molendi, V., additional, Brancato, A., additional, D'Aprile, N., additional, Giappichini, G., additional, Del Vecchio, S., additional, Mantini, G., additional, De Tommasi, F., additional, Meucci, G., additional, Cordoni, M., additional, Bechi, S., additional, Barsotti, L., additional, Baldini, P., additional, Romei, M., additional, Scopelliti, G., additional, Lauri, G., additional, Pestelli, F., additional, Furiozzi, F., additional, Cocchieri, M., additional, Severini, D., additional, Patriarchi, F., additional, Chiocchi, P., additional, Buccolieri, M., additional, Martinelli, S., additional, Wee, A., additional, Angelici, F., additional, Bernardinangeli, M., additional, Proietti, G., additional, Biscottini, B., additional, Panciarola, R., additional, Marinacci, L., additional, Perna, G.P., additional, Gabrielli, D., additional, Moraca, A., additional, Moretti, L., additional, Partemi, L., additional, Gregori, G., additional, Amici, R., additional, Patteri, G., additional, Capone, P., additional, Savini, E., additional, Morgagni, G.L., additional, Paccaloni, L., additional, Pezzuoli, F., additional, Carincola, S., additional, Papi, S., additional, De Crescentini, S., additional, Gerardi, P., additional, Midi, P., additional, Gallenzi, E., additional, Pajes, G., additional, Mancone, C., additional, Di Spirito, V., additional, Di Gennaro, M., additional, Calcagno, S., additional, Toscano, S., additional, Antonicoli, S., additional, Carta, F., additional, Giorgi, G., additional, Comito, F., additional, Daniele, E., additional, Ciarla, O., additional, Gelfo, P.G., additional, Acquaviva, A., additional, Testa, D., additional, Testa, G., additional, Pagliaro, F.A., additional, Russo, F., additional, Vetta, F., additional, Marchese, I., additional, Di Sciascio, G., additional, D'Ambrosio, A., additional, Leggio, F., additional, Del Sindaco, D., additional, Lacchè, A., additional, Avallone, A., additional, Risa, M.P., additional, Azzolini, P., additional, Baldo, E., additional, Giovannini, E., additional, Pulignano, G., additional, Tondo, C., additional, Picchio, E., additional, ani, E., additional, Tanzi, P., additional, Pozzar, F., additional, Farnetti, F., additional, Azzarito, M., additional, Santini, M., additional, Varveri, A., additional, Ferraiuolo, G., additional, Valtorta, C., additional, Gaspardone, A., additional, Barbato, G., additional, Ceci, V., additional, Aspromonte, N., additional, Bellocci, F., additional, Colizzi, C., additional, Fedele, F., additional, Perez, F.I., additional, Galati, A., additional, Rossetti, A., additional, Mainella, A., additional, etta, D., additional, Matteucci, C., additional, Busi, G., additional, De Angelis, A., additional, Farina, G., additional, Granatelli, A., additional, Leone, F., additional, Frasca, F., additional, Di Giovambattista, R., additional, Castellani, G., additional, Massaro, G., additional, Mastrogiuseppe, G., additional, Vacri, A., additional, De Sanctis, F., additional, Cioli, M., additional, Di Luzio, S., additional, Napoletano, C., additional, Piccioni, L.L., additional, De Simone, G., additional, Ottaviano, A., additional, Mazza, V., additional, Spedaliere, C., additional, Staniscia, D., additional, Calgione, E., additional, De Marco, G., additional, Chiacchio, T., additional, Di Napoli, T., additional, Romanzi, S., additional, Salvatore, G., additional, Golino, P., additional, Palermo, A., additional, Mascia, F., additional, Vetrano, A., additional, Vinciguerra, A., additional, Caliendo, L., additional, Longobardi, R., additional, De Caro, G., additional, Di Nola, R., additional, Piemonte, F., additional, Prinzi, D., additional, De Rosa, P., additional, De Rosa, V., additional, Riello, F., additional, Capuano, V., additional, Vecchio, G., additional, Landi, M., additional, Amato, S., additional, Garofalo, M., additional, D'Avino, M., additional, Sensale, P., additional, Maiolica, O., additional, Santoro, R., additional, Caso, P., additional, Miceli, D., additional, Maurea, N., additional, Bianchi, U., additional, Crispo, C., additional, Chiariello, M., additional, Perrone Filardi, P., additional, Russo, L., additional, Capuano, N., additional, Ungaro, G., additional, Vergara, G., additional, Scafuro, F., additional, D'Angelo, G., additional, Campaniello, C., additional, Bottiglieri, P., additional, Volpe, A., additional, Battista, R., additional, De Risi, L., additional, Cardillo, G., additional, Sibilio, G., additional, Marino, A.P., additional, Silvestri, F., additional, Predotti, P., additional, Iervoglini, A., additional, De Matteis, C., additional, Sarnicola, P., additional, Matarazzo, M.M., additional, Baldi, S., additional, Iuliano, V., additional, Astarita, C., additional, Cuccaro, P., additional, Liguori, A., additional, Liguori, G., additional, Gregorio, G., additional, Petraglia, L., additional, Antonelli, G., additional, Amodio, G., additional, De Luca, I., additional, Traversa, D., additional, Franchini, G., additional, Lenti, M.L., additional, Cavallari, D., additional, D'Agostino, C., additional, Scalera, G., additional, Altamura, C.M., additional, Russo, M., additional, Mascolo, A.R., additional, Pettinati, G., additional, Ciricugno, S.A., additional, Scrutinio, D., additional, Passantino, A., additional, Mastrangelo, D., additional, Di Masi, A., additional, De Carne, R., additional, Cannone, M., additional, Dibiase, F., additional, Pensato, M., additional, Loliva, F., additional, Trapani, F., additional, Panettieri, I., additional, Leone, L., additional, Di Biase, M., additional, Carrone, M., additional, Gallone, V., additional, Cocco, F., additional, Costantini, M., additional, Tritto, C., additional, Cavalieri, F., additional, Stella, L., additional, Magliari, F., additional, Callerame, M., additional, De Giorgi, A., additional, Pellegrino, L., additional, Correra, M., additional, Portulano, V., additional, Nisi, G.L., additional, Grassi, G., additional, Cristallo, E., additional, De Laura, D., additional, Salerno, C., additional, Fanelli, R., additional, Villella, M., additional, Pede, S., additional, Renna, A., additional, De Lorenzi, E., additional, Urso, L., additional, Lenti, V., additional, Peluso, A., additional, Baldi, N., additional, Polimeni, G., additional, Palma, P., additional, Lauletta, R., additional, Tagliamonte, E., additional, Cirillo, T., additional, Silvestri, B., additional, Centonze, G., additional, D'Alessandro, B., additional, Truncellito, L., additional, Mecca, D., additional, Petruzzi, M.A., additional, Coviello, R.O.M., additional, Lopizzo, A., additional, telli, M., additional, Barbuzzi, S., additional, Gubelli, S., additional, Germinario, G., additional, Cosentino, N., additional, Mingrone, A., additional, Vico, R., additional, Borrello, G., additional, Mazza, M.L., additional, Cimino, R., additional, Galasso, D., additional, Cassadonte, F., additional, Talarico, U., additional, Perticone, F., additional, Cassano, S., additional, Catapano, F., additional, Calemme, S., additional, Feraco, E., additional, Cloro, C., additional, Misuraca, G., additional, Caporale, R., additional, Vigna, L., additional, Spagnuolo, V., additional, De Rosa, F., additional, Spadafora, G., additional, Zampaglione, G., additional, Russo, R., additional, Schipani, F.A., additional, Ferragina, A.F., additional, Stranieri, D., additional, Musca, G., additional, Carpino, C., additional, Bencardino, P., additional, Raimondo, F., additional, Musacchio, D., additional, Pulitanò, G., additional, Ruggeri, A., additional, Provenzano, A., additional, Salituri, S., additional, Musolino, M., additional, Calandruccio, S., additional, Marrari, A., additional, Tripodi, E., additional, Scali, R., additional, Anastasio, L., additional, Arone, A., additional, Aragona, P., additional, Donnangelo, L., additional, Comito, M.G.A., additional, Bilotta, F., additional, Vaccaro, I., additional, Rametta, R., additional, Ventura, V., additional, Bonvegna, A., additional, Alì, A., additional, Cinnirella, C., additional, Raineri, M., additional, Pompeo, F., additional, Cascio Ingurgio, N., additional, Carini, V., additional, Coco, R., additional, Giunta, G., additional, Leonardi, G., additional, Randazzo, V., additional, Di Blasi, V., additional, Tamburino, C., additional, Russo, G., additional, Mangiameli, S., additional, Cardillo, R., additional, Castelli, D., additional, Inserra, V., additional, Arena, A., additional, Gulizia, M.M., additional, Raciti, S., additional, Rapisarda, G., additional, Romano, R., additional, Prestifilippo, P., additional, Braschi, G.B., additional, Ledda, G., additional, Terrazzino, R., additional, De Caro, M., additional, Scilabra, G., additional, agnino, B., additional, Grassi, R., additional, Di Tano, G., additional, Scimone, G.F., additional, Vasquez, L., additional, Coppolino, C., additional, Casale, A., additional, Castelli, M., additional, D'Urso, G., additional, D'Antonio, E., additional, Lo Presti, L., additional, Badalamenti, E., additional, Conti, P., additional, Sanfilippo, N., additional, Cirrincione, V., additional, Cinà, M.T., additional, Cusimano, G., additional, Taormina, A., additional, Giuliano, P., additional, Bajardi, A., additional, Mandalà, V., additional, Canonico, A., additional, Geraci, G., additional, Sabella, F.P., additional, Enia, F., additional, Floresta, A.M., additional, Lo Cascio, I., additional, Gumina, D., additional, Cavallaro, A., additional, Piccione, G., additional, Ferrante, R., additional, Blandino, M., additional, Iudicello, M.S., additional, Mossuti, E., additional, Romano, G., additional, Lombardo, L., additional, Monastra, P., additional, Di Vincenzo, D., additional, Porcu, M., additional, Orrù, P., additional, Muscas, F., additional, Giardina, G., additional, Corda, M., additional, Locci, G., additional, Podda, A., additional, Ledda, M., additional, Siddi, P., additional, Lai, C., additional, Pili, G., additional, Mercuro, G., additional, Mureddu, G., additional, Ganau, A., additional, Meloni, G., additional, Poddighe, G., additional, and Sanna, G., additional

Published
2017
Full Text
View/download PDF

49. 177Direct his-bundle pacing in cardiac resynchronization therapy

Author

Zanon, F., primary, Marcantoni, L., additional, Pastore, G., additional, Picariello, C., additional, Aggio, S., additional, Lanza, D., additional, Roncon, L., additional, Carraro, M., additional, Conte, L., additional, Rinuncini, M., additional, D'elia, K., additional, Galasso, MP., additional, and Baracca, E., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results